CL2022003008A1 - Procesos para la preparación de un inhibidor de cinasa - Google Patents
Procesos para la preparación de un inhibidor de cinasaInfo
- Publication number
- CL2022003008A1 CL2022003008A1 CL2022003008A CL2022003008A CL2022003008A1 CL 2022003008 A1 CL2022003008 A1 CL 2022003008A1 CL 2022003008 A CL2022003008 A CL 2022003008A CL 2022003008 A CL2022003008 A CL 2022003008A CL 2022003008 A1 CL2022003008 A1 CL 2022003008A1
- Authority
- CL
- Chile
- Prior art keywords
- processes
- preparation
- compound
- kinase inhibitor
- synthetic preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Health & Medical Sciences (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
Abstract
La presente invención se relaciona con procesos para la preparación sintética de inhibidores de c-Met de la Fórmula I, o sales farmacéuticamente aceptables de estos. La presente invención se relaciona además con procesos para la preparación sintética del inhibidor de c-Met, el Compuesto 1, o una sal farmacéuticamente aceptable de este. La presente invención se relaciona también con procesos para la preparación sintética del Compuesto 1.hemifumarato. La invención se relaciona además con procesos a gran escala para la preparación sintética del inhibidor de c-Met, Compuesto 1 y Compuesto 1.hemifumarato.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063017739P | 2020-04-30 | 2020-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022003008A1 true CL2022003008A1 (es) | 2023-06-23 |
Family
ID=76076455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022003008A CL2022003008A1 (es) | 2020-04-30 | 2022-10-28 | Procesos para la preparación de un inhibidor de cinasa |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230192619A1 (es) |
| EP (1) | EP4143169A1 (es) |
| JP (1) | JP2023524692A (es) |
| KR (1) | KR20230005190A (es) |
| CN (1) | CN115461328A (es) |
| AU (1) | AU2021263474A1 (es) |
| BR (1) | BR112022021712A2 (es) |
| CA (1) | CA3176042A1 (es) |
| CL (1) | CL2022003008A1 (es) |
| CO (1) | CO2022015205A2 (es) |
| CR (1) | CR20220551A (es) |
| IL (1) | IL297684A (es) |
| MX (1) | MX2022013528A (es) |
| PE (1) | PE20230110A1 (es) |
| TW (1) | TW202208335A (es) |
| WO (1) | WO2021222673A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019148044A1 (en) * | 2018-01-26 | 2019-08-01 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
| TW202334090A (zh) * | 2021-11-03 | 2023-09-01 | 美商艾克塞里克斯公司 | 用於治療激酶依賴性病症之化合物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4014971A1 (en) * | 2010-07-16 | 2022-06-22 | Exelixis, Inc. | C-met modulator pharmaceutical compositions |
| WO2019148044A1 (en) * | 2018-01-26 | 2019-08-01 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
| CN113329790A (zh) * | 2018-12-13 | 2021-08-31 | 埃克塞里艾克西斯公司 | 激酶抑制剂的结晶形式和盐形式 |
| CN109761899B (zh) * | 2019-02-14 | 2022-11-15 | 广州六顺生物科技股份有限公司 | 喹啉衍生物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物 |
-
2021
- 2021-04-30 EP EP21727657.5A patent/EP4143169A1/en active Pending
- 2021-04-30 PE PE2022002513A patent/PE20230110A1/es unknown
- 2021-04-30 CN CN202180031136.7A patent/CN115461328A/zh active Pending
- 2021-04-30 BR BR112022021712A patent/BR112022021712A2/pt unknown
- 2021-04-30 CR CR20220551A patent/CR20220551A/es unknown
- 2021-04-30 TW TW110115786A patent/TW202208335A/zh unknown
- 2021-04-30 US US17/922,208 patent/US20230192619A1/en active Pending
- 2021-04-30 AU AU2021263474A patent/AU2021263474A1/en active Pending
- 2021-04-30 MX MX2022013528A patent/MX2022013528A/es unknown
- 2021-04-30 CA CA3176042A patent/CA3176042A1/en active Pending
- 2021-04-30 WO PCT/US2021/030035 patent/WO2021222673A1/en active Application Filing
- 2021-04-30 JP JP2022566135A patent/JP2023524692A/ja active Pending
- 2021-04-30 KR KR1020227037607A patent/KR20230005190A/ko active Search and Examination
- 2021-04-30 IL IL297684A patent/IL297684A/en unknown
-
2022
- 2022-10-26 CO CONC2022/0015205A patent/CO2022015205A2/es unknown
- 2022-10-28 CL CL2022003008A patent/CL2022003008A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021222673A1 (en) | 2021-11-04 |
| KR20230005190A (ko) | 2023-01-09 |
| CN115461328A (zh) | 2022-12-09 |
| MX2022013528A (es) | 2022-11-16 |
| BR112022021712A2 (pt) | 2022-12-06 |
| PE20230110A1 (es) | 2023-01-25 |
| CO2022015205A2 (es) | 2022-10-31 |
| EP4143169A1 (en) | 2023-03-08 |
| AU2021263474A1 (en) | 2022-11-17 |
| CA3176042A1 (en) | 2021-11-04 |
| CR20220551A (es) | 2022-12-07 |
| TW202208335A (zh) | 2022-03-01 |
| IL297684A (en) | 2022-12-01 |
| US20230192619A1 (en) | 2023-06-22 |
| JP2023524692A (ja) | 2023-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022003008A1 (es) | Procesos para la preparación de un inhibidor de cinasa | |
| ECSP22057865A (es) | Inhibidores de formas mutantes de egfr | |
| AR116604A1 (es) | Inhibidores de kras g12c | |
| AR107694A1 (es) | Heteroarilos inhibidores de pad4 | |
| AR111960A1 (es) | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación | |
| CL2020000610A1 (es) | Compuestos de bisamida que activan el sarcómero y sus usos. | |
| CO2024001367A2 (es) | Compuestos antivirales | |
| AR126251A1 (es) | Inhibidores de cdk2 | |
| AR121226A1 (es) | Compuestos y usos de estos | |
| CL2020001752A1 (es) | Derivado de oxi-fluoropiperidina como inhibidor de quinasa. | |
| CO2021016504A2 (es) | Inhibidores de cdk | |
| CU20210023A7 (es) | Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4 | |
| CO2022015874A2 (es) | Inhibidores de cd38 | |
| UY37941A (es) | Derivados de bencimidazol y sus usos | |
| AR116951A1 (es) | Sales cristalinas de un inhibidor de calicreína plasmática | |
| CO2021014210A2 (es) | Compuestos de pirrol | |
| AR085308A1 (es) | Formas solidas del inhibidor de girasa (r)-1-etil-3-[6-fluoro-5-[2-(1-hidroxi-1-metil-etil)pirimidin-5-il]-7-(tetrahidrofuran-2-il)-1h-benzimidazol-2-il]urea | |
| NI202100012A (es) | Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 | |
| AR105821A1 (es) | COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T | |
| CO2022008719A2 (es) | Compuestos para modular la actividad de fxr y usos de los mismos | |
| CL2023003758A1 (es) | Pirimidinil-pirazoles sustituidos como inhibidores de cdk2 | |
| DOP2021000254A (es) | Compuestos de pirrolidina | |
| DOP2024000077A (es) | Compuestos de cd73 | |
| CO2021017202A2 (es) | Compuestos tricíclicos | |
| AR116428A1 (es) | Compuestos de 6-fluoro-2-metilbenzo[d]tiazol-5-ilo |